Ondine Biomedical (LON:OBI) Hits New 1-Year High After Insider Buying Activity

Ondine Biomedical Inc. (LON:OBI) shares hit a new 52-week high during mid-day trading on Friday after an insider bought additional shares in the company. The stock traded as high as C$13.30 and last traded at C$13.30, with a volume of 209400 shares traded. The stock had previously closed at C$12.50.

Specifically, insider Nicolas Loebel bought 25,000 shares of Ondine Biomedical stock in a transaction dated Wednesday, February 5th. The stock was bought at an average price of C$13.00 per share, for a total transaction of C$325,000.00. Also, insider Carolyn Cross acquired 149,225 shares of the stock in a transaction dated Monday, February 3rd. The shares were bought at an average cost of C$13.00 per share, with a total value of C$1,939,925.00.

Ondine Biomedical Stock Performance

The stock has a 50 day simple moving average of C$9.52 and a 200 day simple moving average of C$8.10. The company has a market cap of C$3.69 billion, a price-to-earnings ratio of -443.33 and a beta of 0.10. The company has a quick ratio of 8.26, a current ratio of 0.80 and a debt-to-equity ratio of 1,847.37.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.